Taiwan-based Formosa Pharmaceuticals (Formosa) announced that the company has entered into an exclusive licensing agreement with Medvisis Switzerland AG (Medvisis) in Switzerland and Liechtenstein, ...

for exclusive rights to the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007), a marketed innovative treatment of post-operative inflammation and pain following ocular ...